Headlines about Aldeyra Therapeutics (NASDAQ:ALDX) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Aldeyra Therapeutics earned a daily sentiment score of 0.15 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 44.6288359638815 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the news articles that may have impacted Accern Sentiment Analysis’s scoring:
- Aldeyra Therapeutics, Inc. (ALDX) Short Interest Down 45.3% in September (americanbankingnews.com)
- Aldeyra Therapeutics, Inc. (ALDX) Downgraded to Sell at Zacks Investment Research (americanbankingnews.com)
- Aldeyra Therapeutics Announces New Data at 2017 Research & Development Day – Markets Insider (markets.businessinsider.com)
Shares of Aldeyra Therapeutics (NASDAQ ALDX) opened at 7.00 on Tuesday. The firm’s market cap is $43.72 million. Aldeyra Therapeutics has a 12-month low of $3.80 and a 12-month high of $11.90. The company has a 50 day moving average price of $6.63 and a 200-day moving average price of $5.10.
Aldeyra Therapeutics (NASDAQ:ALDX) last issued its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.02. Analysts expect that Aldeyra Therapeutics will post ($1.51) EPS for the current year.
Several analysts have recently weighed in on the company. Zacks Investment Research raised Aldeyra Therapeutics from a “hold” rating to a “buy” rating and set a $4.75 price objective for the company in a research note on Thursday, August 10th. Canaccord Genuity reiterated a “buy” rating and set a $27.00 target price (up previously from $12.00) on shares of Aldeyra Therapeutics in a research report on Wednesday, September 13th. Cowen and Company reiterated an “outperform” rating and set a $14.00 target price (up previously from $9.00) on shares of Aldeyra Therapeutics in a research report on Thursday, September 14th. ValuEngine upgraded Aldeyra Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Tuesday, September 12th. Finally, HC Wainwright set a $18.00 target price on Aldeyra Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Two research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $15.95.
TRADEMARK VIOLATION NOTICE: “Aldeyra Therapeutics (NASDAQ:ALDX) Earns Daily Media Sentiment Rating of 0.15” was posted by BBNS and is the property of of BBNS. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://baseballnewssource.com/markets/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-aldeyra-therapeutics-aldx-share-price/1697772.html.
In other Aldeyra Therapeutics news, major shareholder Life Sciences Maste Perceptive bought 200,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 19th. The stock was acquired at an average price of $7.25 per share, with a total value of $1,450,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 28.40% of the stock is currently owned by company insiders.
Aldeyra Therapeutics Company Profile
Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.
Receive News & Ratings for Aldeyra Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc. and related companies with our FREE daily email newsletter.